Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Roger Song maintained a Buy rating on Kailera Therapeutics (KLRA) with a $48 price target. This follows TD Cowen's recent decision to also keep a Buy rating on the stock, setting a higher target of $57. Both firms express positive sentiment towards the healthcare company.
In a report released today, Roger Song from Jefferies maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $48.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Song covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Kailera Therapeutics, Inc., and TG Therapeutics. According to TipRanks, Song has an average return of 4.5% and a 43.68% success rate on recommended stocks.
In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $57.00 price target.